CLINICAL TRIAL SUMMARY

MDACC Study No:2007-0395 (clinicaltrials.gov NCT No: NCT00464620)
Title:SARC 009: A Phase II Trial of Dasatinib in Advanced Sarcoma
Principal Investigator:Shreyaskumar R. Patel
Treatment Agent:Dasatinib
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if dasatinib can help to
control the disease in patients with advanced sarcoma. The safety of this drug
will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Sarcoma
Phase of Study:Phase II
Treatment Agents:Dasatinib
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:None
Supported By:Bristol-Myers Squibb Pharmaceutical Research Institute
Sarcoma Alliance for Research through Collaboration, SARC
Return Visit:Prestudy visit
Every 4 wks for the first 6 mos, then every 6 weeks for the next 6 mos, and
then every 3 mos while in the treatment portion of the study.
Repeat CT or MRI every 2 mos for 6 mos, then every 3 mos for 2 years from
registration.
Home Care:Patients will self administer Dasatinib orally twice daily at home.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Shreyaskumar R. Patel
Dept:Sarcoma Medical Oncology
For Clinical Trial Enrollment:713-792-3626
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults